BA
MRNA icon

Bridgewater Associates’s Moderna MRNA Stock Holding History

Bridgewater Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$807K Sell
11,527
-63,295
-85% -$3.27M ﹤0.01% 864
2026
Q1 		$3.8M Buy
74,822
+59,641
+393% +$2.78M 0.02% 484
2025
Q4 		$448K Sell
15,181
-207,029
-93% -$5.62M ﹤0.01% 981
2025
Q3 		$5.74M Buy
+222,210
New +$6.2M 0.02% 463
2025
Q1 		– Sell
-605,782
Closed -$25.2M – 752
2024
Q4 		$25.2M Buy
+605,782
New +$29M 0.12% 140
2024
Q3 		– Sell
-15,309
Closed -$1.82M – 867
2024
Q2 		$1.82M Buy
+15,309
New +$1.94M 0.01% 552
2023
Q3 		– Sell
-30,865
Closed -$3.75M – 788
2023
Q2 		$3.75M Buy
30,865
+25,489
+474% +$3.4M 0.02% 357
2023
Q1 		$826K Sell
5,376
-2,301
-30% -$380K 0.01% 581
2022
Q4 		$1.38M Sell
7,677
-9,758
-56% -$1.6M 0.01% 593
2022
Q3 		$2.06M Sell
17,435
-231,722
-93% -$35.2M 0.01% 557
2022
Q2 		$35.6M Buy
249,157
+202,476
+434% +$28.9M 0.15% 133
2022
Q1 		$8.04M Buy
46,681
+43,042
+1,183% +$7.25M 0.03% 342
2021
Q4 		$924K Sell
3,639
-4,670
-56% -$1.37M 0.01% 589
2021
Q3 		$3.2M Buy
+8,309
New +$3.06M 0.02% 362

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Bridgewater Associates's MRNA Position: Q2 2026 in Review

Bridgewater Associates reduced its Moderna (MRNA) stake by 85% in Q2 2026, selling an estimated $3.27M and leaving 11,527 shares worth $807K. The position accounts for ﹤0.01% of the portfolio, ranked #864.

Bridgewater Associates first reported a position in MRNA in Q3 2021 and has held it in 14 quarters since. The position peaked at $35.6M in Q2 2022. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Bridgewater Associates held 11,527 shares of Moderna worth $807K as of Q2 2026.
  • Bridgewater Associates sold 63,295 Moderna shares in Q2 2026, an estimated $3.27M.
  • Moderna made up ﹤0.01% of Bridgewater Associates's portfolio in Q2 2026, its #864 holding.
  • Bridgewater Associates first reported a position in Moderna in Q3 2021 and has held it in 14 quarters since.
  • Bridgewater Associates's Moderna position peaked at $35.6M in Q2 2022.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.